Deutsche Bank
APGE

Deutsche Bank’s Apogee Therapeutics APGE Stock Holding History

Deutsche Bank’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1M Buy
98,979
+7,558
+8% +$681K ﹤0.01% 975
2026
Q1 		$7.69M Buy
91,421
+12,060
+15% +$876K ﹤0.01% 1143
2025
Q4 		$5.99M Buy
79,361
+2,814
+4% +$177K ﹤0.01% 1233
2025
Q3 		$3.04M Buy
76,547
+52,838
+223% +$2.02M ﹤0.01% 1535
2025
Q2 		$1.03M Sell
23,709
-5,160
-18% -$196K ﹤0.01% 2076
2025
Q1 		$1.08M Sell
28,869
-2,870
-9% -$111K ﹤0.01% 2112
2024
Q4 		$1.44M Buy
31,739
+10,709
+51% +$546K ﹤0.01% 2043
2024
Q3 		$1.24M Buy
21,030
+4,836
+30% +$232K ﹤0.01% 2021
2024
Q2 		$637K Sell
16,194
-3,012
-16% -$146K ﹤0.01% 2219
2024
Q1 		$1.28M Buy
19,206
+11,535
+150% +$504K ﹤0.01% 1882
2023
Q4 		$214K Buy
7,671
+3,064
+67% +$61.4K ﹤0.01% 2838
2023
Q3 		$98.1K Buy
+4,607
New +$101K ﹤0.01% 3168

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Deutsche Bank's APGE Position: Q2 2026 in Review

Deutsche Bank increased its Apogee Therapeutics (APGE) stake by 8.3% in Q2 2026, buying an estimated $681K and bringing the position to 98,979 shares worth $13.1M. The position accounts for ﹤0.01% of the portfolio, ranked #975.

Deutsche Bank first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Deutsche Bank held 98,979 shares of Apogee Therapeutics worth $13.1M as of Q2 2026.
  • Deutsche Bank bought 7,558 Apogee Therapeutics shares in Q2 2026, an estimated $681K.
  • Apogee Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #975 holding.
  • Deutsche Bank first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.